NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. PLEASURE, MD. Predicting Motor Decline and Disability in Parkinson Disease
|
|
- Homer Floyd
- 7 years ago
- Views:
Transcription
1 SECTION EDITOR: DAVID E. PLEASURE, MD Predicting Motor Decline and Disability in Parkinson Disease A Systematic Review NEUROLOGICAL REVIEW Connie Marras, MD; Paula Rochon, MD, MPH; Anthony E. Lang, MD Context: The clinical course of Parkinson disease (PD) varies from patient to patient. A number of studies investigating predictors of prognosis in patients with PD have been performed. Objective: To summarize evidence on predicting the rate of motor decline and increasing disability in early PD. Data Sources: English-language and French-language literature cited in the MEDLINE database ( ). Study Selection: Cohort and case-control studies investigating associations between clinical features and subsequent motor impairment or disability were selected. Data Extraction: Study methods and results were abstracted by a single reviewer. Data Synthesis: The results of 13 studies were summarized qualitatively. Study methods were highly variable, particularly regarding the choice of outcome measure. Baseline motor impairment and cognitive impairment are probable predictors of more rapid motor decline and disability. A lack of tremor at onset and older age both appear to be predictive of increasing disability, but conflicting results exist for their association with the rate of change of motor impairment. Family history of PD does not appear to be prognostically important. The prognostic value of many other factors studied is uncertain owing to conflicting or unconfirmed results. Conclusions: Uncertainty remains about the prognostic importance of many baseline clinical features in PD. Greater baseline impairment, early cognitive disturbance, older age, and lack of tremor at onset appear to be adverse prognostic factors. Arch Neurol. 2002;59: From the Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, University Health Network, University of Toronto (Drs Marras and Lang), the Kunin-Lunenfeld Applied Research Unit, Baycrest Center for Geriatric Care, University of Toronto (Dr Rochon), and the Institute for Clinical and Evaluative Sciences (Dr Rochon), Toronto, Ontario. THE CLINICAL course of Parkinson disease (PD) varies from patient to patient, and this variability has led to a number of studies investigating predictors of prognosis in PD. Predicting the clinical course of PD is important for several reasons. It helps patients recently diagnosed with a progressive disorder make social and occupational decisions that take into account their likely future physical functioning. Understanding the variables associated with disease progression also guides the design and interpretation of clinical trials of neuroprotective and symptomatic therapy. It would be important, for example, to ensure balance between groups on the basis of important prognostic factors. The heterogeneity of PD has been noted by many authors. For example, in their 1999 report of the Sydney, Australia, multicenter study of PD, Hely et al 1 showed that despite the wide availability of current treatment strategies and excluding patients developing signs and symptoms atypical for PD in follow-up, during 10 years of observation, 9 of 126 patients progressed to confinement to bed or a wheelchair unless aided, whereas 13 patients remained without significant functional restriction. Such variability leaves us with the challenge of predicting the future course of PD in individuals and groups of patients. We conducted a systematic review to identify predictors of motor decline and disability in patients with PD. We focused on motor impairment and disability because motor impairment is the defining feature of this illness and it affects patients largely through increasing physical disability. METHODS DATA SOURCE Using the MEDLINE database, we searched the English-language and French-language literature published from 1966 through January 31, 1724
2 Table 1. Cohort and Case-Control Studies of Motor Prognosis in Patients With Parkinson Disease* Source, Year Setting/Inclusion Criteria No. of Patients/Total Follow-up, y Outcome Measures Diamond et al, Trial cohort followed since starting 54/54 6 Change in UCLA scale score levodopa Diamond et al, Trial cohort followed since starting 70/ Change in UCLA scale score levodopa Ferraz et al, Tertiary care/follow-up 6 mo 63/ (mean) HY stage: better, worse, or same Tertiary care/hy stage 1-2, 31/NS 2 (mean) Progression to HY stage 3 untreated throughout Goetz et al, Tertiary care/follow-up 4 y 221/434 4 Change in UPDRS motor score Chastang, Tertiary care/follow-up 4 y 164/ Time to motor decline and moderate to severe deterioration Guillard et al, Tertiary care/treated with levodopa 356/356 NS Time to loss of independence Hely et al, Trial cohort/hy stage 1-3, untreated 76/125 5 Change in CURS 10 points Hely et al, Trial cohort/hy stage 1-3, untreated 130/ Change in CURS 20 points Tertiary care/disease duration 2 y 218/229 NS Percentage of patients disabled Tertiary care/follow-up 3 y 297/NS 6.4 (mean) Change in UPDRS ADL and motor scores Tertiary care/follow-up 1 y 237/NS 3.3 (mean) Change in UPDRS motor score Starkstein et al, Consecutive patients/tertiary care 92/106 1 Change in NWUDS, HY stage, tremor, rigidity, and bradykinesia scores *HY indicates Hoehn and Yahr; UCLA, University of California, Los Angeles; UPDRS, Unified Parkinson s Disease Rating Scale; CURS, Columbia University Rating Scale; ADL, activities of daily living; NWUDS, Northwestern University Disability Scale; and NS, not stated. Data are given as the number of patients reported on in the series/the total number of patients prior to exclusion for insufficient baseline data or loss to follow-up. Of 221 patients, 100 were randomly selected The medical subject headings Parkinson disease and prognosis were combined with either of the text words progression or natural history, and we limited the search to clinical trials or cohort studies. STUDY SELECTION We reviewed 457 titles and abstracts for reports investigating the association between progression of motor features or disability and patient or disease-related factors (as opposed to the effect of an intervention). These articles and relevant articles from their reference lists were obtained for review. Reports published only in abstract form and reports of predictive factors for dyskinesias or motor fluctuations were excluded. We included only studies that prospectively documented disease progression, whether this was within the context of the study (prospective cohort studies) or from medical records (retrospective cohort studies and case-control studies). Studies that made a single observation of outcome were considered to be cross-sectional and were excluded. DATA EXTRACTION Study methods and results were abstracted by one of us (C.M.). Studies were assessed for methodologic quality using 5 criteria adapted from the Evidence-Based Medicine Working Group s Users Guide to the Medical Literature criteria for appraising an article about prognosis 2 and from the methodologic and quality scoring instrument developed by Cho and Bero 3 (criterion 5 of our instrument). 1. Patients within 5 years of symptom onset at first observation. 2. Median or mean follow-up of at least 2 years. 3. Greater than 80% of patients followed up. 4. Clearly defined and reproducible outcome measures. 5. Known confounders accounted for in the design or analysis. When examining the prognostic significance of other variables, baseline status on the outcome of interest, disease duration, and treatment allocation (if applicable) should be adjusted for statistically or should be balanced between groups. OUTCOME MEASURES Studies were grouped by category of outcome measure, either disability or motor impairment. RESULTS DATA SYNTHESIS Of the studies assessed, 41 articles were identified that investigated factors (other than treatment) associated with outcome in PD; 27 of these were excluded from our review: 13 were cross-sectional studies, 10 studies investigated only nonmotor outcomes (cognitive dysfunction, 8 studies; mortality or institutionalization, 2 studies), 1 study investigated factors associated with time to requiring therapy with levodopa, and 3 were review articles. One cohort study was excluded because the source of subjects (inpatients having had a computed tomographic scan of the head) was felt to significantly limit the external validity of the study. 4 One prospective cohort study, 5 11 retrospective cohort studies, 1,4,6-15 and 1 case-control study 16 were retained for review. Table 1 provides a summary of their methods. PREDICTING DISABILITY Variables investigated for their association with increasing disability are presented in Table 2. Presentation without tremor (bradykinesia/rigidity type) was found to be a marker of poor prognosis in 2 studies by Guillard et al 9 and Chastang, 10 and a trend toward this result was noted in 2 other studies. 13,15 Guillard et al 9 and 1725
3 Table 2. Variables Investigated for Association With Increasing Disability in Patients With Parkinson Disease* Variable Bradykinesia/rigidity type (vs tremor at onset or tremor dominant) Predictive Cognitive disturbance in the first year Initial lack of independence Babinski response at baseline Older age at onset Diamond et al, Male sex Depression Starkstein et al, Source Not Predictive Diamond et al, Living in a rural area Ferraz et al, Family history of Parkinson disease Smoking history Early dyskinesias or fluctuations Birth trauma Environmental exposures Physical and emotional stress Vitamin intake *Includes Hoehn and Yahr stage as an outcome. Chastang, , and Guillard et al, , used overlapping samples of patients. There was a trend toward a worse prognosis in patients without tremor at onset. Measles prior to age 18 years and chemical, herbicide, or well water exposure were analyzed separately. Chastang 10 did not report their results quantitatively. Hoehn and Yahr 13 reported that at the end of their follow-up period, 19% of patients with tremor at onset were disabled vs 24% of patients without tremor at onset. Goetz et al 15 found an odds ratio of 0.43 for progression to Hoehn and Yahr stage 3 when tremor was the first symptom. In a fifth study investigating the dominant symptom type of PD (postural instability gait disorder vs tremor), Kapadia 14 found that subjects with a tremor-dominant subtype (they did not classify patients by initial symptom) experienced slower worsening of Unified Parkinson s Disease Rating Scale (UPDRS) activities of daily living (ADL) scores. Early lack of physical independence, a positive Babinski sign, and cognitive disturbance within the first year of symptoms were found to be poor prognostic factors by Chastang, 10 again with a subjectively defined outcome and no quantitative result given. A positive Babinski sign and cognitive disturbance within the first year would be unusual for patients with PD, raising the possibility that these signs are markers of alternative diagnoses with a worse prognosis. Older patients had a poorer prognosis in 4 of 5 studies. 8,9,13-15 Diamond et al 8 found that older patients had poorer outcomes after 6 years of levodopa therapy. Patients older than 60 years experienced little net change in UCLA (University of California, Los Angeles) scale scores (99 to 92) compared with a net score change of 39 points (92 to 53) in those younger than 50 years (ie, younger patients maintained their improvement with levodopa; higher scores indicate greater disease severity). Goetz et al 15 found that patients who progressed to Hoehn and Yahr stage 3 during 2 years of observation were older (mean age, 65 years) than a group of patients matched for disease duration and initial Hoehn and Yahr stage who did not progress beyond stage 2 (mean age, 52 years). Older age at onset was reported to predict earlier loss of independence by Guillard et al 9 and a more rapid worsening of UPDRS ADL scores by Kapadia. 14 Hoehn and Yahr 13 did not find an association between increasing age and disability. Three studies generated differing results regarding the prognostic importance of depression in patients with PD. 5,9,10 Using a prospective design, Starkstein et al 5 found depression at baseline to predict greater decline in Northwestern University Disability Scale score (2.7 point deterioration in patients with depression vs 0.1 point mean improvement in individuals without depression during 1 year). This contrasts with 2 retrospective studies that did not detect an association between depression and future disability (disability not defined). 9,10 A family history of PD had no significant prognostic value in 4 studies. 9,10,13,15 Other variables investigated for their association with increasing disability with conflicting or negative results are presented in Table 2. PREDICTING MOTOR IMPAIRMENT Factors investigated for association with motor impairment are shown in Table 3. Dementia at baseline was found to be associated with faster motor decline in 2 studies 6,12 ; however, in only one did this remain significant after adjusting for other baseline factors. 12 Louis et al 12 found that the UPDRS motor scores of patients with dementia were, on average, 7.9 points higher (higher scores represent greater severity) at each annual visit than in those without dementia at baseline. Although there was adjustment for several baseline factors, there was no adjustment made for initial motor score. The degree of baseline motor impairment was found to be positively correlated with later impairment in 2 studies. Louis et al 12 found that a baseline Schwab and England ADL score of 70 or less (lower scores indicate greater disability) was associated with mean UPDRS motor scores 11.7 points higher at each annual visit over a mean follow-up of 3.3 years compared with those with ADL scores greater than
4 Chastang 10 found that the median time to significant motor impairment (not defined) was 6 years in patients with mild akinesia at baseline and 4 years in patients with more severe akinesia. In contrast, Goetz et al 16 found that baseline UPDRS scores showed a negative correlation (r= 0.25) with the change in scores during the subsequent 4 years. The correlation is modest, and this could represent a tendency for outlying observations to regress to the mean. Older age was associated with more rapid progression of motor impairment in 2 of 4 studies. 1,8 Hely et al 1 studied a cohort of patients followed prospectively for 10 years. Each increase in age of 10 years was associated with an odds ratio of 2.41 (95% confidence interval, ) for an increase in Columbia University Rating Scale score by 20 or more points. Diamond et al 8 found a significant effect of age using the UCLA scale, as described previously. They noted that tremor and rigidity changed little and that the most decline occurred in gait, balance, rising from a chair, and rolling over in bed. In contrast, 2 other studies did not find age at onset to be associated with increasing UPDRS motor scores. 12,14 Sex was not found to be related to motor decline in 4 studies. 6,7,12,14 A fifth study by Hely et al 1 found that female sex was predictive of a deterioration in modified Columbia University Rating Scale score of more than 20 points in univariate (odds ratio not given) but not multivariate analysis. Conversely, men did more poorly in 2 studies using disability 9 and increasing UPDRS ADL scores 14 as outcome measures (Table 2). Two studies investigated the relationship between type of presentation (tremor vs bradykinesia/rigidity type) and progression of motor impairment. In contrast with the studies of disability, this was not found to be an important predictor of motor impairment in either study. 1,14 Other factors with contradictory or negative results can be seen in Table 3. METHODOLOGIC APPRAISAL Of 13 studies, 9 did not identify their cohort by duration of disease. 1,5,6,9-12,14,16 Two studies followed their cohort for less than 2 years, 5,11 and 2 studies did not achieve greater than 80% follow-up of their cohort. 11,16 Three studies did not objectively define the outcomes used, 9,10,13 and 6 studies did not account for potential confounders in their analysis COMMENT SUMMARY OF RESULTS Our systematic review identified trends for the prognostic importance of 4 baseline factors. First, those with more severe baseline impairment continue to be more impaired later in the disease course. Second, there is some inconsistent evidence that a presentation without tremor (predominant bradykinesia/rigidity or postural instability) and increasing age may be predictors of more rapidly increasing disability but not of more rapidly increasing motor impairment. Regarding age, this Table 3. Variables Investigated for Association With Increasing Motor Impairment in Patients With Parkinson Disease Source, Year Variable Predictive Not Predictive Bradykinesia/rigidity presentation Dementia Hely et al, * Schwab and England score 70 Lack of independence Chastang, More severe rigidity Chastang, Greater tremor severity Hely et al, * Baseline UPDRS score Goetz et al, Early (prestudy) disease progression Older age Diamond et al, Hely et al, Older age at onset Longer illness duration Goetz et al, Female sex Hely et al, * Diamond et al, Depression Starkstein et al, 5 Starkstein et al, Living in a rural area Ferraz et al, Balance disorder Goetz et al, Symmetry of disease Ethnicity Level of education *The variable was predictive in univariate but not multivariate analysis. Hely et al, , and Hely et al, , used the sample of patients at 5 and 10 years of follow-up, respectively. UPDRS indicates Unified Parkinson s Disease Rating Scale. Depression predicts a greater change in Hoehn and Yahr stage but not tremor, rigidity, or bradykinesia scores. raises the possibility that measures of disability are detecting an association between increasing age and non-pd related disability. Finally, cognitive impairment at baseline also appears to be associated with future disability and motor impairment. Sex does not appear to have prognostic importance for progression of motor impairment; for changes in disability, the evidence is conflicting. Family history of PD was consistently found not to be an important prognostic factor for motor impairment or disability. However, it is important to consider that family history may not be a significant prognostic factor for sporadic PD but rare familial forms may have distinct prognoses. For example, mutations in the parkin gene can cause a recessively inherited parkinsonism clinically indistinguishable from idiopathic PD other than by younger average age at onset and a relatively benign course. 17 Epidemiologic studies may not detect this association because of the rarity of these types of PD (especially in older cohorts 1727
5 in the case of parkin mutations 18 ) and their geographic clustering. Prognostic factors may also be different depending on the outcome being evaluated. We did not consider other important outcomes such as cognitive deterioration, mortality, institutionalization, or the development of dyskinesias and motor fluctuations. For example, younger age has been shown in several different studies to predispose to the development of drug-induced dyskinesias earlier in the disease course. 19,20 METHODOLOGIC VARIABILITY ACROSS STUDIES We noted conflicting results on many potential prognostic factors that have been investigated, and this may be due in part to variable methods used by the investigators. For example, defining a cohort by (mild) symptom severity or only by having the disease rather than by duration of disease favors the selection of patients with more slowly progressive PD who live longer and have more mild symptoms for a longer duration. Also, short duration of follow-up limits the ability to detect important prognostic factors in a disease that often lasts more than a decade. Of 13 studies, 6 did not indicate whether they excluded patients developing atypical symptoms during the follow-up period. 5,7-9,11,12 Patients with atypical symptoms may have distinct disorders with distinct prognostic factors, despite early clinical features entirely consistent with PD. Finally, outcome measures varied markedly across studies. The use of different outcome scales in different ways may further contribute to apparently conflicting results. It would be helpful for future research to make use of previously used outcome measures to build on the results of past studies. CONCLUSIONS Our review identified baseline severity of motor symptoms and possibly early cognitive impairment as factors influencing the progression of motor symptoms and disability. Increasing age and lack of rest tremor appear to predict more rapid accumulation of disability, but not necessarily motor impairment. Conflicting results were found concerning the prognostic importance of many other factors, and this may result, in part, from methodologic variability across studies. Accepted for publication June 14, Author contributions: Study concept and design (Drs Marras and Lang); acquisition of data (Dr Marras); analysis and interpretation of data (Drs Marras, Rochon, and Lang); drafting of the manuscript (Drs Marras and Rochon); critical revision of the manuscript for important intellectual content (Drs Marras and Lang); obtained funding (Dr Marras); administrative, technical, and material support (Dr Lang); study supervision (Drs Rochon and Lang). This study was supported by a Research Training Award (Dr Marras) and an Investigator Award (Dr Rochon) from the Canadian Institutes of Health Research, Ottawa, Ontario, and the University of Toronto Clinician Scientist Training Program, Toronto, Ontario (Dr Marras). Corresponding author and reprints: Anthony E. Lang, MD, Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital 11-MP, 399 Bathurst St, Toronto, Ontario M5G 2S8, Canada. REFERENCES 1. Hely MA, Morris JG, Traficante R, Reid WG, O Sullivan DJ, Williamson PM. The Sydney multicentre study of Parkinson s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry. 1999;67: Laupacis A, Wells G, Richardson S, Tugwell P, for the Evidence-Based Medicine Working Group. Users guides to the medical literature, V: how to use an article about prognosis. JAMA. 1994;272: Cho MK, Bero L. Instruments for assessing the quality of drug studies published in the medical literature. JAMA. 1994;272: Scigliano G, Musicco M, Soliveri P, et al. Progression and prognosis in Parkinson s disease in relation to concomitant cerebral or peripheral vasculopathy. Adv Neurol. 1996;69: Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson s disease. J Neurol Neurosurg Psychiatry. 1992; 55: Hely MA, Morris JG, Reid WG, et al. Age at onset: the major determinant of outcome in Parkinson s disease. Acta Neurol Scand. 1995;92: Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. An examination of male-female differences in progression and mortality of Parkinson s disease. Neurology. 1990;40: Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Effect of age at onset on progression and mortality in Parkinson s disease. Neurology. 1989;39: Guillard A, Chastang C, Fenelon G. Long-term study of 416 cases of Parkinson disease: prognostic factors and therapeutic implications [in French]. Rev Neurol (Paris). 1986;142: Guillard A, Chastang C. Long-term prognostic factors in Parkinson s disease [in French]. Rev Neurol (Paris). 1978;134: Ferraz HB, Andrade LA, Tumas V, Calia LC, Borges V. Rural or urban living and Parkinson s disease. Arq Neuropsiquiatr. 1996;54: Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K. Progression of parkinsonian signs in Parkinson disease. Arch Neurol. 1999;56: Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. ;17: Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001;58: Goetz CG, Tanner CM, Stebbins GT, Buchman AS. Risk factors for progression in Parkinson s disease. Neurology. 1988;38: Goetz CG, Stebbins GT, Blasucci LM. Differential progression of motor impairment in levodopa-treated Parkinson s disease. Mov Disord. 2000;15: Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson s disease and mutations in the parkin gene. N Engl J Med. 2000;342: Oliveri RL, Zappia M, Annesi G, et al. The parkin gene is not involved in lateonset Parkinson s disease. Neurology. 2001;57: Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopainduced dyskinesias and response fluctuations in young-onset Parkinson s disease. Neurology. 1991;41(2 pt 1): Gomez AG, Jorge R, Garcia S, Scipioni O, Gershanik O. Clinical and pharmacological differences in early- versus late-onset Parkinson s disease. Mov Disord. 1997;12:
Parkinson Disease Levodopa-Induced Dyskinesia. Christopher Kenney, MD Novartis Pharmaceuticals
Parkinson Disease Levodopa-Induced Dyskinesia Christopher Kenney, MD Novartis Pharmaceuticals Disclosures Dr. Kenney is a full-time employee of Novartis Pharmaceuticals Corporation The opinions expressed
More informationPARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS
PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS De Anna Looper, RN CHPN Corporate Clinical Consultant / Legal Nurse Consultant Carrefour Associates L.L.C. PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS
More informationWhat is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician
What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician Overview of presentation Case history Video example pre and post treatment Historical review PD in the UK Epidemiology and aetiology Making
More informationWhat factors determine poor functional outcome following Total Knee Replacement (TKR)?
Specific Question: What factors determine poor functional outcome following Total Knee Replacement ()? Clinical bottom line All groups derived benefit from undergoing a, reviews suggests that the decision
More informationMr James Garrard University of Leicester May 2014
Parkinson s disease exemplifies the art and science of geriatric medicine. Introduction First described by Dr. James Parkinson in the classic essay The Shaking Palsy in 1817 (1), Parkinson s disease is
More informationParkinson s prevalence in the United Kingdom (2009)
Parkinson s prevalence in the United Kingdom (2009) Contents Summary 3 Background 5 Methods 6 Study population 6 Data analysis 7 Results 7 Parkinson's prevalence 7 Parkinson's prevalence among males and
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION Prognosis of Parkinson Disease Risk of Dementia and Mortality: The Rotterdam Study Lonneke M. L. de Lau, MD; C. Maarten A. Schipper, PhD; Albert Hofman, MD, PhD; Peter J. Koudstaal,
More informationSUMMARY This PhD thesis addresses the long term recovery of hemiplegic gait in severely affected stroke patients. It first reviews current rehabilitation research developments in functional recovery after
More informationPrognosis of Parkinson s Disease: Time to Stage III, IV, V, and to Motor Fluctuations
Movement Disorders Vol. 21, No. 9, 2006, pp. 1384 1395 2006 Movement Disorder Society Prognosis of Parkinson s Disease: Time to Stage III, IV, V, and to Motor Fluctuations Kenichi Sato, MD,* Taku Hatano,
More informationRecommendations Oxford Centre for Evidence-based Medicine Oxford Centre for Evidence-based Medicine
Recommendations for Naming Study Design and Levels of Evidence for Structured Abstracts in the Journal of Orthopedic & Sports Physical Therapy (JOSPT) Last revised 07-03-2008 The JOSPT as a journal that
More informationABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD
ABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD What is Parkinson s Disease? Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually,
More informationStroke Rehabilitation Triage Severe Strokes
The London Stroke Rehab Data Base Project Robert Teasell MD FRCPC Professor and Chair-Chief Department of Phys Med Rehab London Ontario Retrospective Data Bases In stroke rehab limited funding for clinical
More informationSign up for IWH s free e-alert/newsletter
Sign up for IWH s free e-alert/newsletter Please fill out the Sign-up Form (available up front), go to www.iwh.on.ca/e-alerts and sign up online Every three months, you will receive an e-mail message directing
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationClinical Research in Parkinson s Disease: The Advances, Challenges, and Importance of Rater Training
Clinical Research in Parkinson s Disease: The Advances, Challenges, and Importance of Rater Training Marian A. Ormont, MD epharmasolutions, A WIRB-Copernicus Group Company April is Parkinson s disease
More informationDEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE
1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff
More informationUnmet Needs for Parkinson s Disease Therapeutics
Unmet Needs for Parkinson s Disease Therapeutics Coalition Against Major Diseases & FDA Workshop October 20, 2014 Caroline M Tanner MD, PhD Director, Parkinson's Disease Research Education and Clinical
More informationCoenzyme Q10. Information Sheet
Coenzyme Q10 What is Coenzyme Q10? Coenzyme Q10 (or CoQ10) is a substance present in every cell of the body. A coenzyme is a very small molecule that enhances the function of enzymes, particularly in the
More informationAsymptomatic HIV-associated Neurocognitive Disorder (ANI) Increases Risk for Future Symptomatic Decline: A CHARTER Longitudinal Study
Asymptomatic HIV-associated Neurocognitive Disorder (ANI) Increases Risk for Future Symptomatic Decline: A CHARTER Longitudinal Study Robert Heaton, PhD 1, Donald Franklin, BS 1, Steven Woods, PsyD 1,
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationCLINICAL PRACTICE GUIDELINES FOR PHYSICAL THERAPY IN PATIENTS WITH PARKINSON'S DISEASE
CLINICAL PRACTICE GUIDELINES FOR PHYSICAL THERAPY IN PATIENTS WITH PARKINSON'S DISEASE Charbel MACARI Physical Therapist, AUBMC Master in Neurological Rehabilitation OUTLINE Definition, Epidemiology and
More informationParkinson's s disease - a
Parkinson's Disease Parkinson's s disease - a progressive disorder of the nervous system that affects movement. The most common perception of Parkinson s is the patient having tremors. Hands shaking, inability
More informationRisk Factors for Alcoholism among Taiwanese Aborigines
Risk Factors for Alcoholism among Taiwanese Aborigines Introduction Like most mental disorders, Alcoholism is a complex disease involving naturenurture interplay (1). The influence from the bio-psycho-social
More informationFrequent headache is defined as headaches 15 days/month and daily. Course of Frequent/Daily Headache in the General Population and in Medical Practice
DISEASE STATE REVIEW Course of Frequent/Daily Headache in the General Population and in Medical Practice Egilius L.H. Spierings, MD, PhD, Willem K.P. Mutsaerts, MSc Department of Neurology, Brigham and
More informationDoes referral from an emergency department to an. alcohol treatment center reduce subsequent. emergency room visits in patients with alcohol
Does referral from an emergency department to an alcohol treatment center reduce subsequent emergency room visits in patients with alcohol intoxication? Robert Sapien, MD Department of Emergency Medicine
More informationParkinson s Disease: Factsheet
Parkinson s Disease: Factsheet Tower Hamlets Joint Strategic Needs Assessment 2010-2011 Executive Summary Parkinson s disease (PD) is a progressive neuro-degenerative condition that affects a person s
More informationClinical characteristics of neuroleptic-induced parkinsonism
J Neural Transm (2001) 108: 1299 1308 Clinical characteristics of neuroleptic-induced parkinsonism S. Hassin-Baer 1,*, P. Sirota 2, A. D. Korczyn 1,3, T. A. Treves 1,**, B. Epstein 2, H. Shabtai 1, T.
More informationProduct Development News
Article from: Product Development News May 2006 Issue 65 Features Comfort Food for an Actuary: Cognitive Testing in Underwriting the Elderly 1 by Eric D. Golus, Laura Vecchione and Thomas Ashley Eric D.
More informationTitle The Mental Health of Adolescents Living with Potentially Fatal Arrhythmia: A Systematic Review of the Literature
PROSPERO Registration of Systematic Review Title The Mental Health of Adolescents Living with Potentially Fatal Arrhythmia: A Systematic Review of the Literature Registration - - - to be registered in
More informationParkinson s Disease (PD)
Parkinson s Disease (PD) Parkinson s disease (PD) is a movement disorder that worsens over time. About 1 in 100 people older than 60 has Parkinson s. The exact cause of PD is still not known, but research
More informationLewy body dementia Referral for a Diagnosis
THE Lewy Body society The more people who know, the fewer people who suffer Lewy body dementia Referral for a Diagnosis Lewy Body Dementias REFERRAL FOR A DIAGNOSIS In the UK people with all forms of dementia
More informationCaregiving Impact on Depressive Symptoms for Family Caregivers of Terminally Ill Cancer Patients in Taiwan
Caregiving Impact on Depressive Symptoms for Family Caregivers of Terminally Ill Cancer Patients in Taiwan Siew Tzuh Tang, RN, DNSc Associate Professor, School of Nursing Chang Gung University, Taiwan
More informationSinemet (Parkinson's Disease) - Forecast and Market Analysis to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2834728/ Sinemet (Parkinson's Disease) - Forecast and Market Analysis to 2022 Description: Sinemet (Parkinson s Disease) - Forecast
More informationImportant Predictors of Outcome in Patients with Cervical Spondylotic Myelopathy and Radiculopathy undergoing Surgery
Important Predictors of Outcome in Patients with Cervical Spondylotic Myelopathy and Radiculopathy undergoing Surgery Michael G. Fehlings Professor of Neurosurgery Vice Chair Research, Department of Surgery
More informationIf several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.
General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary
More informationRörelserubbningar och Parkinson, hur svårt kan det vara. En översikt och problematisering av en folksjukdom Örjan Skogar, MD,PhD
Rörelserubbningar och Parkinson, hur svårt kan det vara En översikt och problematisering av en folksjukdom Örjan Skogar, MD,PhD Man räknar med att 11-19 personer /100 000 invånare insjuknar i Parkinson
More informationHow To Write Long Term Care Insurance
By Lori Boyce, AVP Risk Management and R&D Underwriting long term care insurance: a primer Every day Canadians die, are diagnosed with cancer, have heart attacks and become disabled and our insurance solutions
More informationFSH Society s 2014 Biennial FSHD Connect Meeting: Natural History Studies
FSH Society s 2014 Biennial FSHD Connect Meeting: Natural History Studies Raymond A. Huml, MS, DVM, RAC Executive Director, Head, Global Biosimilars Business Development and Strategic Planning, Quintiles
More informationPrimary Endpoints in Alzheimer s Dementia
Primary Endpoints in Alzheimer s Dementia Dr. Karl Broich Federal Institute for Drugs and Medical Devices (BfArM) Kurt-Georg-Kiesinger-Allee 38, D-53175 Bonn Germany Critique on Regulatory Decisions in
More informationPrevalence of Parkinsonism and its aetiological subtypes within patients with movement disorders
Research papers Prevalence of and its aetiological subtypes within patients with movement disorders D G S V D Gajasinghe* AL 2002 batch of students, Faculty of Medicine, University of Colombo Abstract
More informationClinical Study Design and Methods Terminology
Home College of Veterinary Medicine Washington State University WSU Faculty &Staff Page Page 1 of 5 John Gay, DVM PhD DACVPM AAHP FDIU VCS Clinical Epidemiology & Evidence-Based Medicine Glossary: Clinical
More informationLong Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine)
1 of 8 USE OF CHOLINESTERASE (AChE) INHIBITORS The cholinesterase inhibitor anti-dementia drugs are indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer s
More informationMOTION AND E-MOTION. Andrea Cavanna MD PhD FRCP
MOTION AND E-MOTION Andrea Cavanna MD PhD FRCP Consultant in Behavioural Neurology, BSMHFT, Birmingham, UK Hon Professor in Neuropsychiatry, Aston University, Birmingham, UK Hon Reader in Neuropsychiatry,
More informationin the Elderly Thomas Robinson, MD Surgery Grand Rounds March 10 th, 2008
Post- Operative Delirium in the Elderly Thomas Robinson, MD Surgery Grand Rounds March 10 th, 2008 What is the most common post-operative complication in elderly patients? What is the most common post-operative
More informationHow To Treat Aphasic Depression
Antipsychotic Use in Patients with Parkinson s Disease 단국의대 정신과 이석범 Difficulties in Parkinson's disease Motor symptoms Neuropsychiatric syndromes Severe Disability Cognitive impairment 2 Neuropsychiatric
More informationCRITERIA FOR AD DEMENTIA June 11, 2010
CRITERIA F AD DEMENTIA June 11, 2010 Alzheimer s Disease Dementia Workgroup Guy McKhann, Johns Hopkins University (Chair) Bradley Hyman, Massachusetts General Hospital Clifford Jack, Mayo Clinic Rochester
More informationIBADAN STUDY OF AGEING (ISA): RATIONALE AND METHODS. Oye Gureje Professor of Psychiatry University of Ibadan Nigeria
IBADAN STUDY OF AGEING (ISA): RATIONALE AND METHODS Oye Gureje Professor of Psychiatry University of Ibadan Nigeria Introduction The Ibadan Study of Ageing consists of two components: Baseline cross sectional
More informationManagement of Parkinson s Disease in Primary Care
Management of Parkinson s Disease in Primary Care Dr June Tan National University Hospital System (NUHS) Division of Neurology Senior Consultant Topics: Diagnosing PD Choice of medication in the de novo
More informationPARKINSON S DISEASE INTRODUCTION. Parkinson s disease is defined as a disease of the nervous system that affects voluntary movement.
PARKINSON S DISEASE INTRODUCTION Parkinson s disease is a disorder of the brain and the nervous system. It is one of the more common neurological diseases in people over the age of 60, and it is more common
More informationREHABILITATION MEDICINE by PROFESSOR ANTHONY WARD
REHABILITATION MEDICINE by PROFESSOR ANTHONY WARD What is Rehabilitation Medicine? Rehabilitation Medicine (RM) is the medical specialty with rehabilitation as its primary strategy. It provides services
More informationMeeting the Needs of Aging Persons. Aging in Individuals with a
Meeting the Needs of Aging Persons with Developmental Disabilities Cross Network Collaboration for Florida Aging in Individuals with a Developmental Disability Module 3 Based on ADRC training developed
More informationDepression in the Elderly: Recognition, Diagnosis, and Treatment
Depression in the Elderly: Recognition, Diagnosis, and Treatment LOUIS A. CANCELLARO, PhD, MD, EFAC Psych Professor Emeritus and Interim Chair ETSU Department of Psychiatry & Behavioral Sciences Diagnosis
More informationIt has been estimated that approximately one third of US
THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 12, Number 4, 2006, pp. 395 399 Mary Ann Liebert, Inc. Open-Label Trial Regarding the Use of Acupuncture and Yin Tui Na in Parkinson s Disease
More informationAlzheimer s disease. What is Alzheimer s disease?
Alzheimer s disease What is Alzheimer s disease? What we know about dementia and Alzheimer s disease Alzheimer s disease is the most common of a large group of disorders known as dementias. It is an irreversible
More informationAmerican Academy of Neurology Section on Neuroepidemiology Resident Core Curriculum
10/01/01 American Academy of Neurology Section on Neuroepidemiology Resident Core Curriculum A Curriculum for Clinical Neuroepidemiology and Evidence-based Neurology 1. Introduction and Justification The
More informationDepartment of Veterans Affairs Health Services Research and Development - A Systematic Review
Department of Veterans Affairs Health Services Research & Development Service Effects of Health Plan-Sponsored Fitness Center Benefits on Physical Activity, Health Outcomes, and Health Care Costs and Utilization:
More informationManaging depression after stroke. Presented by Maree Hackett
Managing depression after stroke Presented by Maree Hackett After stroke Physical changes We can see these Depression Emotionalism Anxiety Confusion Communication problems What is depression? Category
More informationPost Traumatic Stress Disorder (PTSD) Karen Elmore MD Robert K. Schneider MD Revised 5-11-2001 by Robert K. Schneider MD
Post Traumatic Stress Disorder (PTSD) Karen Elmore MD Robert K. Schneider MD Revised 5-11-2001 by Robert K. Schneider MD Definition and Criteria PTSD is unlike any other anxiety disorder. It requires that
More informationCompetency 1 Describe the role of epidemiology in public health
The Northwest Center for Public Health Practice (NWCPHP) has developed competency-based epidemiology training materials for public health professionals in practice. Epidemiology is broadly accepted as
More informationFalls Risk Assessment: A Literature Review. The purpose of this literature review is to determine falls risk among elderly individuals and
Falls Risk Assessment: A Literature Review Purpose The purpose of this literature review is to determine falls risk among elderly individuals and identify the most common causes of falls. Also included
More informationSummary of health effects
Review of Findings on Chronic Disease Self- Management Program (CDSMP) Outcomes: Physical, Emotional & Health-Related Quality of Life, Healthcare Utilization and Costs Summary of health effects The major
More informationPredictors of Physical Therapy Use in Patients with Rheumatoid Arthritis
Predictors of Physical Therapy Use in Patients with Rheumatoid Arthritis Maura Iversen,, PT, DPT, SD, MPH 1,2,3 Ritu Chhabriya,, MSPT 4 Nancy Shadick, MD 2,3 1 Department of Physical Therapy, Northeastern
More informationDementia: Delivering the Diagnosis
Dementia: Delivering the Diagnosis Daniel D. Christensen, M.D. Clinical Professor of Psychiatry Clinical Professor of Neurology Adjunct Professor of Pharmacology University of Utah Diagnosing Dementia
More informationBachelor s graduates who pursue further postsecondary education
Bachelor s graduates who pursue further postsecondary education Introduction George Butlin Senior Research Analyst Family and Labour Studies Division Telephone: (613) 951-2997 Fax: (613) 951-6765 E-mail:
More informationTowards Ambulatory Motor Monitoring: Measuring Dyskinesia During Activities of Daily Living. Webinar Will Begin at 12:00 PM EDT
Towards Ambulatory Motor Monitoring: Measuring Dyskinesia During Activities of Daily Living Webinar Will Begin at 12:00 PM EDT Outline Motor Fluctuations and Levodopa-induced Dyskinesia Challenges with
More informationThe CAM-S Score for Delirium Severity Training Manual and Coding Guide
The CAM-S Score for Delirium Severity Training Manual and Coding Guide Please address questions to: Sharon K. Inouye, M.D., MPH Professor of Medicine, Harvard Medical School Milton and Shirley F. Levy
More information2014 Neurologic Physical Therapy Professional Education Consortium Webinar Course Descriptions and Objectives
Descriptions and Neuroplasticity Health care providers are facing greater time restrictions to render services to the individual with neurological dysfunction. However, the scientific community has recognized
More informationParkinson s Disease; March 5, 2016. Providence Rehabilitation Services Presents: Treatment strategies specific to subtype.
Providence Rehabilitation Services Presents: Parkinson s Disease; One size DOES NOT fit all. Treatment strategies specific to subtype. Presented by: Mike Studer, PT, MHS, NCS, CEEAA, CWT, CSST March 5,
More informationCENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE
MANAGEMENT CENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE Parkinson s Disease is classically determined by the triad or rest tremor (usually starting in one arm) with bradykinesia (slowing of
More informationMRC Autism Research Forum Interventions in Autism
MRC Autism Research Forum Interventions in Autism Date: 10 July 2003 Location: Aim: Commonwealth Institute, London The aim of the forum was to bring academics in relevant disciplines together, to discuss
More information1 Risk Factors for Prolonged Disability After Whiplash Injury: A Prospective Study. Spine: Volume 30(4), February 15, 2005, pp 386-391
1 Risk Factors for Prolonged Disability After Whiplash Injury: A Prospective Study Spine: Volume 30(4), February 15, 2005, pp 386-391 Gun, Richard Townsend MB, BS; Osti, Orso Lorenzo MD, PhD; O'Riordan,
More informationResearch 2004-2006. Theresa A. Zesiewicz, MD FAAN Parkinson s Disease and Movement Disorders Center USF
Research 2004-2006 Theresa A. Zesiewicz, MD FAAN Parkinson s Disease and Movement Disorders Center USF 1. Essential Tremor Most common adult movement disorder in the world 1. Zesiewicz TA, Elble R, Louis
More informationWHODAS 2.0 World Health Organization Disability Assessment Schedule 2.0 36-item version, self-administered
The APA is offering a number of emerging measures for further research and clinical evaluation. These patient assessment measures were developed to be administered at the initial patient interview and
More informationGlossary of Methodologic Terms
Glossary of Methodologic Terms Before-After Trial: Investigation of therapeutic alternatives in which individuals of 1 period and under a single treatment are compared with individuals at a subsequent
More informationCARE MANAGEMENT FOR LATE LIFE DEPRESSION IN URBAN CHINESE PRIMARY CARE CLINICS
CARE MANAGEMENT FOR LATE LIFE DEPRESSION IN URBAN CHINESE PRIMARY CARE CLINICS Dept of Public Health Sciences February 6, 2015 Yeates Conwell, MD Dept of Psychiatry, University of Rochester Shulin Chen,
More informationParkinson's disease. Definition. Symptoms
Parkinson's disease Definition Parkinson's disease is a progressive disorder of the nervous system that affects your movement. It develops gradually, sometimes starting with a barely noticeable tremor
More informationHow To Find Out If The Gulf War And Health Effects Of Serving In The Gulf Wars Are Linked To Health Outcomes
Gulf War and Health: Update of Health Effects of Serving in the Gulf War Statement of Stephen L. Hauser, M.D. Professor and Chair of Neurology University of California, San Francisco, School of Medicine
More informationHow to test ocular movements in PSP Jan Kassubek
How to test ocular movements in PSP Jan Kassubek Universitätsklinik für Neurologie, Ulm Bedside Screening: PSP initially slowing of vertical saccades slowing of downward saccades is considered the hallmark
More informationNursing Care of Patients with Movement Disorders. Catholic Health 2 nd Annual Neurorehab Symposium November 1, 2014
Nursing Care of Patients with Movement Disorders Catholic Health 2 nd Annual Neurorehab Symposium November 1, 2014 Types of Movement Disorders Parkinson s disease Huntington s disease Dystonia Tremors
More informationKEY POINTS TOWARDS QUALITY GERIATRIC CARE
KEY POINTS TOWARDS QUALITY GERIATRIC CARE Carmel Bitondo Dyer, MD Professor and Director, Geriatric and Palliative Medicine Division Interim Chief of Staff, LBJ Hospital and Associate Dean of Harris County
More informationHoehn and Yahr Staging of Parkinson's Disease
Hoehn and Yahr Staging of Parkinson's Disease, Unified Parkinson Disease Rating Scale (UPDRS), and Schwab and England Activities of Daily Living Disclaimer: The information and reference materials contained
More informationDiabetes Prevention in Latinos
Diabetes Prevention in Latinos Matthew O Brien, MD, MSc Assistant Professor of Medicine and Public Health Northwestern Feinberg School of Medicine Institute for Public Health and Medicine October 17, 2013
More informationBiogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest
Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest Cycle C June 2, 2015 1 Introduction The landscape for the treatment of relapsing Multiple Sclerosis (MS) has quickly evolved over
More informationCancer Screening. Robert L. Robinson, MD, MS. Ambulatory Conference SIU School of Medicine Department of Internal Medicine.
Cancer Screening Robert L. Robinson, MD, MS Ambulatory Conference SIU School of Medicine Department of Internal Medicine March 13, 2003 Why screen for cancer? Early diagnosis often has a favorable prognosis
More informationCollaborative Care for Alzheimer s Disease
The Health Care Workforce for Older Americans: Promoting Team Care Institute of Medicine Symposium October 2008 Collaborative Care for Alzheimer s Disease Christopher M. Callahan, MD Cornelius and Yvonne
More informationSYNOPSIS. Risperidone: Clinical Study Report CR003274
SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:
More information1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:
1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance
More informationImproving Health for People with Compensable Injuries. Ian Cameron University of Sydney
Improving Health for People with Compensable Injuries Ian Cameron University of Sydney Summary Definitions Two stories Hypothesis 1 People with compensable injuries have worse health (than people without
More informationUpdate on Treatment of the Dementias
Update on Treatment of the Dementias Mark Pippenger, MD Behavioral Neurology Associate Clinical Professor of Neurology University of Arkansas for Medical Sciences Disclosures I will be discussing off-label
More informationUnhappy on the job by Margot Shields
33 by Margot Shields Keywords: employment, job satisfaction, occupational health, work, work schedule tolerance The vast majority of Canadian workers were with their jobs in 2002, but approximately 1 in
More informationOptimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria
Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria AUTHORS Juan Luis Ruiz-Peña, Pablo Duque, and Guillermo Izquierdo Address: Unidad
More informationLocal Clinical Trials
Local Clinical Trials The Alzheimer s Association, Connecticut Chapter does not officially endorse any specific research study. The following information regarding clinical trials is provided as a service
More informationDepression is a debilitating condition that places
11 Stress and depression in the employed population Margot Shields Abstract Objectives This article describes stress levels among the employed population aged 18 to 75 and examines associations between
More informationWritten Example for Research Question: How is caffeine consumption associated with memory?
Guide to Writing Your Primary Research Paper Your Research Report should be divided into sections with these headings: Abstract, Introduction, Methods, Results, Discussion, and References. Introduction:
More informationß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate
ABN Guidelines for 2007 Treatment of Multiple Sclerosis with ß-interferon and Glatiramer Acetate Published by the Association of British Neurologists Ormond House, 27 Boswell Street, London WC1N 3JZ Contents
More informationPrepared by:jane Healey (Email: janie_healey@yahoo.com) 4 th year undergraduate occupational therapy student, University of Western Sydney
1 There is fair (2b) level evidence that living skills training is effective at improving independence in food preparation, money management, personal possessions, and efficacy, in adults with persistent
More informationFebruary 25, 2015. Summary
February 25, 2015 Director Public Service Bodies and Government Division Excise and Gst/Hst Rulings Directorate Canada Revenue Agency 14 th Floor, Place de Ville, Tower A 320 Queen Street Ottawa, ON K1A
More informationMCPS Special Education Parent Summit
MCPS Special Education Parent Summit May 17, 2014 Rockville High School 2100 Baltimore Road Rockville, MD 20851 When ADHD Is Not ADHD: ADHD Look-Alikes and Co-occurring Disorders David W. Holdefer MCPS
More informationBorderline Personality Disorder NEA-BPD Meet and Greet New York, NY October 21, 2011
Borderline Personality Disorder NEA-BPD Meet and Greet New York, NY October 21, 2011 John M. Oldham, M.D. Senior Vice President and Chief of Staff The Menninger Clinic; Professor and Executive Vice Chair
More informationPrevention of Acute COPD exacerbations
December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal
More information